Marketing of antipsychotic drugs attackedBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7132.645g (Published 28 February 1998) Cite this as: BMJ 1998;316:645
- Deborah Josefson
- San Francisco
Drug companies in the United States are facing criticism for advertising psychotrophic drugs directly to the general public and to patients. One drug company is even offering university scholarships to schizophrenic patients who switch to their new antipsychotic drug.
Last August the Food and Drug Administration changed the rules to allow advertisers to market drugs directly to the public, as long as they provided adequate information about a drug's indications and side effects, or the advertisement directed the consumer to where this information could be found. Consumers in the United States are now deluged with glossy pharmaceutical advertisements in magazines, on television, and on the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial